Cipla bidding for Belgian drug maker
18 August 2015 | News | By BioSpectrum Bureau
Cipla bidding for Belgian drug maker
(Photo Courtesy: www.customerexperiencereport.com)
An acquisition which is pegged at $1.3 billion, Indian drug maker Cipla is eying Kremers Urban, the specialty generics drug business of the US $4 billion Belgian drug maker UCB.
Initially, Lupin and Torrent Pharma were also contending for the bid, but dropped out later.
Kremers sales revenue stood at $463 million for 2014.
